RxDoctor Payments DataLook up a doctor →

Luis Alvarez, MD

Adult Medicine · Boca Raton, FLNPI 1861412587

Payments from drug & device makers

$7,867in general payments, 2019–2025

Across 359 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$613
  • Exact Sciences$540
  • Lilly USA, LLC$462
  • Novo Nordisk$429
  • Otsuka America Pharmaceutical, Inc.$383
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,74698%
  • Education$1212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,867 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$117,004
Medicare patients
233
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$119,884
EliquisApixaban41$51,639
JardianceEmpagliflozin33$47,861
TrulicityDulaglutide25$45,436
FarxigaDapagliflozin Propanediol31$45,351
RybelsusSemaglutide13$32,108
MounjaroTirzepatide24$25,775
JanuviaSitagliptin Phosphate22$24,484
EntrestoSacubitril/Valsartan12$23,721
TradjentaLinagliptin15$23,282
LinzessLinaclotide22$22,801
XareltoRivaroxaban12$20,152
Tresiba Flextouch U-200Insulin Degludec14$18,689
BrilintaTicagrelor17$11,840
Breo ElliptaFluticasone/Vilanterol13$7,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$429$151,99196 claims
Lilly USA, LLCTrulicity, Mounjaro$462$71,21049 claims
Boehringer IngelheimJardiance, Tradjenta$256$71,14348 claims
AstraZenecaFarxiga, Brilinta$1,962$57,19048 claims
PfizerEliquis$613$51,63941 claims
MerckJanuvia$72$24,48422 claims
NovartisEntresto$89$23,72112 claims
Johnson & JohnsonXarelto$39$20,15212 claims
GSKBreo Ellipta$163$7,87613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →